Core Viewpoint - Xuan Bamboo Biotech-B (02575) has seen a nearly 3% increase in stock price, currently trading at 66.95 HKD, following the announcement of its innovative drug, Pirlosil, being included in the 2025 National Basic Medical Insurance Directory [1] Group 1: Company Announcement - On December 8, Xuan Bamboo Biotech-B announced that its self-developed innovative drug, Pirlosil tablets (brand name: Xuan Yuening®), has been included in the 2025 National Basic Medical Insurance Directory [1] - The 2025 National Basic Medical Insurance Directory will officially take effect on January 1, 2026 [1] Group 2: Market Impact - The inclusion of Pirlosil in the insurance directory is expected to enhance the affordability and accessibility of the drug for patients, which will facilitate its market promotion and increase sales scale [1] - The company plans to actively cooperate in implementing the insurance policy, continue to promote hospital access, expand core markets, and increase market coverage to improve patient access to medication [1]

相关事件 本次医保谈判结果有助于轩竹生物进一步提高轩悦宁®在患者中的可负担性和可及性，有利于进一步推 动该药物的市场推广、提升销售规模，对轩竹生物的长期经营发展具有积极影响。轩竹生物将积极配合 推进医保政策落地，持续推进医院准入工作、拓展核心市场及广阔市场的覆盖，以期不断提升患者的用 药可及性。 格隆汇12月8日丨四环医药(00460.HK)宣布，集团旗下非全资附属公司轩竹生物科技股份有限公司("轩 竹生物")自主研发的创新药吡洛西利片(商品名：轩悦宁®)首次纳入《国家基本医疗保险、生育保险和 工伤保险药品目录(2025年)》(「2025国家基本医保目录」)。2025国家基本医保目录将于2026年1月1日 正式执行. 四环医药(00460.HK)：创新药轩悦宁®首次纳入国家基本医保药品目录 四环医药(00460.HK)：安久卫® 成功续约2025年国家基本医保药品目录 ...